Literature DB >> 15233216

Radiolabeled somatostaitin analogs in the treatment of neuroendocrine tumors: experience of the National Cancer Institute of Milano using high dose of 111In-pentetreotide in metastatic neuroendocrine gastroenteropancreatic tumors.

E Bombardieri1, E Seregni, G Savelli, C Villano, M R Castellani, F Cirillo, F Pallotti, S Fracassi, C Chiesa, A Chiti, E Bajetta.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 15233216

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  2 in total

1.  Improved quality of life in patients treated with Peptide radionuclides.

Authors:  T Traub-Weidinger; M Raderer; M Uffmann; P Angelberger; A Kurtaran; M Leimer; J Preitfellner; R Dudczak; I Virgolini
Journal:  World J Nucl Med       Date:  2011-07

Review 2.  Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives.

Authors:  Roberto Baldelli; A Barnabei; L Rizza; A M Isidori; F Rota; P Di Giacinto; A Paoloni; F Torino; S M Corsello; A Lenzi; M Appetecchia
Journal:  Front Endocrinol (Lausanne)       Date:  2014-02-07       Impact factor: 5.555
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.